Buy PharmaCyte Biotech

In: Tips

25 Mar 2015

Hi Everybody,

Everyday there’s a new biotech running, creating profit opportunities for savvy traders.

With this in mind we found a nice looking biotech, that has received FDA orphan drug designation for their pancreatic cancer treatment. They are in phase 2b of clinical trials which are expected to commence this year.

That’s not all, this pancreatic treatment is based on the company’s cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R) which may also be useful in treatment for other forms of cancer as well as diabetes.

The fact is this company has a real shot at making some waves as larger investors are more willing to take chances on little known biotechs due to the current market condition.

Our alert for Wednesday is:
PharmaCyte Biotech, Inc.
Ticker symbol: PMCB
Last price: $0.10

PMCB is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R).

PMCB’s patented Cell-in-a-Box treatment, has earned FDA ‘orphan drug designation’, for the treatment of pancreatic cancer. They will be executing Phase 2b of their clinical trials vs. a treatment using Eli Lilly’s Gemzar and Celgene’s Abraxane┬«.

Celgene is a billion dollar market cap company, and Eli Lilly is even bigger…if PMCB’s trials are successful this could end up as a wild ride for early investors.

But even before any of that happens, the sheer potential of this story as it makes its rounds could make for some major price swings.

The smallcap biotech sector is leading the market, and PMCB is a beautiful opportunity at capitalizing on this trend.

Make sure you’re ready to book your profits with PMCB!

Free Stock TipsAs always, do your own research, don’t chase gaps, use limit orders to enter positions, always use stop loss orders to protect your position, and take profits when you are in a position to do so.

Good Trading

Comment Form